[Skip to Content]
[Skip to Content Landing]
Article
October 9, 1995

Drug-Related Morbidity and MortalityA Cost-of-Illness Model

Author Affiliations

From the Center for Pharmaceutical Economics, College of Pharmacy, The University of Arizona, Tucson.

Arch Intern Med. 1995;155(18):1949-1956. doi:10.1001/archinte.1995.00430180043006
Abstract

Background:  Preventable drug-related morbidity and mortality represent a serious medical problem that urgently requires expert attention. The costs to society of the misuse of prescription medications, in terms of morbidity, mortality, and treatment, can be immense. To date, research has primarily documented increased rates of hospitalization secondary to medication noncompliance and/or adverse drug effects.

Objectives:  To develop a conceptual model of drug-related morbidity and mortality, and to estimate the associated costs in the ambulatory setting in the United States.

Methods:  A probability pathway model was developed to estimate the cost of drug-related morbidity and mortality in the United States. Pharmacist practitioners were surveyed to determine conditional probabilities of therapeutic outcomes owing to drug therapy. Health care utilization and associated costs owing to negative therapeutic outcomes were estimated.

Results:  Drug-related morbidity and mortality was estimated to cost $76.6 billion in the ambulatory setting in the United States. The largest component of this total cost was associated with drug-related hospitalizations. When assumptions of the model were varied, the estimated cost ranged from a conservative estimate of $30.1 to $136.8 billion in a worst-case scenario.

Conclusions:  The cost of drug-related morbidity and mortality in the ambulatory setting in the United States is considerable and should be considered in health policy decisions with regard to pharmaceutical benefits. Policies and services should be developed to reduce and prevent drug-related morbidity and mortality.(Arch Intern Med. 1995;155:1949-1956)

References
1.
Hepler CD, Strand LM.  Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm . 1990;47:533-543.
2.
Strand LM, Cipolle R, Morley PC.  Drug-related problems: their structure and function. Drug Intell Clin Pharm . 1990;24:1093-1097.
3.
Manasse HR Jr.  Medication use in an imperfect world, I: drug misadventuring as an issue of public policy. Am J Hosp Pharm . 1989;46:929-944.
4.
Manasse HR Jr.  Medication use in an imperfect world, II: drug misadventuring as an issue of public policy. Am J Hosp Pharm . 1989;46:1141-1152.
5.
Talley RB, Laventurier MF.  Drug-induced illness. JAMA . 1974;229:1043.Article
6.
The Case for America's Pharmaceutical Research Companies . Washington, DC: Pharmaceutical Research and Manufacturers of America; 1994.
7.
Smith DL.  The effect of patient noncompliance on health care costs. Med Interface . (April) 1993:74.
8.
Sullivan SD, Kreling DH, Hazlet TK.  Noncompliance with medication regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ . 1990;2:19-33.
9.
Einarson TR.  Drug-related hospital admissions. Ann Pharmacother . 1993;27: 832-840.
10.
Col N, Fanale JE, Kronholm P.  The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med . 1990; 150:841-845.Article
11.
McKenney JM, Harrison WL.  Drug-related hospital admissions. Am J Hosp Pharm . 1976;33:792-795.
12.
Ives TJ, Bentz EJ, Gwyther RE.  Drug-related admissions to a family medicine service. Arch Intern Med . 1987;147:1117-1120.Article
13.
Bergman U, Wiholm BE.  Drug-related problems causing admissions to a medical clinic. Eur J Clin Pharmacol . 1981;20:193-200.Article
14.
Grymonpre RB, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR.  Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc . 1988;36:1092-1098.
15.
Noncompliance With Medications: An Economic Tragedy With Important Implications for Health Care Reform . Baltimore, Md: The Task Force for Compliance; 1993.
16.
La Piana Simonsen L.  What are pharmacists dispensing most often? top 200 drugs of 1992. Pharm Times . (April) 1993:29-44.
17.
1992 Physicians Fee Guide . Augusta, Ga: HealthCare Consultants Inc; 1992.
18.
Borgsdorf LR, Miano JS, Knapp KN.  Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm . 1994;51:772-777.
19.
AHA Hospital Statistics, 1992-93 Edition . Chicago, III: American Hospital Association; 1994.
20.
 Nursing home utilization by current residents: United States, 1985. Vital Health Stat 13 . 1989;NO. (102) :39.
21.
 Discharges from nursing homes: 1985 National Nursing Home Survey. Vital Health Stat 13 . 1990;No. (103) :29.
22.
Barr JT, Schumacher GE.  Decision analysis and pharmacoeconomic evaluations.  In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics . Cincinnati, Ohio: Harvey Whitney Books; 1991:113-133.
23.
Decision Analysis by TreeAge: DATA for Windows, v2.5 Users Manual . Boston, Mass: TreeAge Software Inc; 1994.
24.
Schappert SM. National Ambulatory Medical Care Survey: 1991 Summary . Hyattsville, Md: National Center for Health Statistics; 1993;No. 230.
25.
Briggs A, Schulpher M, Buxton M.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ . 1994;3: 95-104.Article
26.
McCaig LF. National Hospital Ambulatory Medical Care Survey: 1992 Emergency Department Summary . Hyattsville, Md: National Center for Health Statistics; 1994;No. 245.
27.
Wolf AM, Colditz GA.  The cost of obesity: the US perspective. Pharmaco Economics . 1994;5( (suppl 1) ):34-37.Article
28.
Costs of Diabetes . Alexandria, Va: American Diabetes Association; 1993.
29.
Costs of Cardiovascular Diseases . Dallas, Tex: American Heart Association; 1993.
30.
Rice DP, Hodgson TA, Kopstein AN.  The economic costs of illness: a replication and update. Health Care Financ Rev . 1985;7:61-80.
31.
Hodgson TA, Meiners MR.  Cost-of-illness methodology: a guide to current practices and procedures. Milbank O . 1982;60:429-462.
32.
Drummond MF.  Cost-of-illness studies: a major headache. PharmacoEconomics . 1992;2:1-4.Article
33.
Shiell A, Gerard K, Donaldson C.  Cost of illness studies: an aid to decision-making? Health Policy . 1987;8:317-323.Article
34.
Davey PJ, Leeder SR.  The cost of migraine: more than just a headache? PharmacoEconomics . 1992;2:5-7.Article
35.
Lakshmanan MC, Hershey CO, Breslau D.  Hospital admissions caused by iatrogenic disease. Arch Intern Med . 1986;146:1931-1934.Article
36.
Montamat SC, Cusack BJ, Vestal RE.  Management of drug therapy in the elderly. N Engl J Med . 1989;321:303-309.Article
37.
American Pharmaceutical Association. An APhA White Paper on the Role of the Pharmicist in Comprehensive Medication Use Management: The Delivery of Pharmaceutical Care . Washington, DC: American Pharmaceutical Association; 1992.
38.
 ASHP statement on pharmaceutical care. Am J Hosp Pharm . 1993;50:1720-1723.
39.
 Coalition for Consumer Access to Pharmaceutical Care. ACCP Report . 1993; 13:5-8.
40.
Implementing pharmaceutical care.  Proceedings of an invitational conference conducted by the American Society of Hospital Pharmacists and the ASHP Research and Education Foundation, March 12-15,1993, San Antonio, Texas. Am J Hosp Pharm . 1993;50:1585-1656.
41.
MacKeigan LD, Bootman JL.  A review of cost-benefit and cost-effectiveness analyses of clinical pharmacy services. J Pharm Market Manage . 1988;2:63-84.Article
42.
Willett MS, Bertch KE, Rich DS, Ereshefsky LE.  Prospectus on the economic value of clinical pharmacy services. Pharmacotherapy . 1989;9:45-56.
43.
Britton ML, Lurvey PL.  Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm . 1991;48:265-270.
44.
Taylor JT, Kathman MS.  Documentation of cost savings from decentralized clinical pharmacy services at a community hospital. Am J Hosp Pharm . 1991; 48:1467-1470.
45.
Haig GM, Kiser LA.  Effect of pharmacist participation on a medical team on costs, charges, and length of stay. Am J Hosp Pharm . 1991;48:1457-1462.
46.
Lobas NH, Lepinski PW, Abramowitz PW.  Effects of pharmaceutical care on medication cost and quality of care in an ambulatory-care clinic. Am J Hosp Pharm . 1992;49:1681-1688.
47.
Torok N, Brown G.  The economic impact of clinical pharmacists' unsolicited recommendations. Hosp Pharm . 1992;27:1052-1060.
48.
Kimberlin CL, Berardo DH, Pendergast JF, McKenzie LC.  Effects of an education program for community pharmacists on detecting drug-related problems in elderly patients. Med Care . 1993;31:451-468.Article
49.
Miller SW, Warnock R, Marshall LL, Blankenship G.  Cost savings and reduction of medication-related problems as a result of consultant pharmacy intervention. Consult Pharm . 1993;8:1265-1272.
50.
Hatoum HT, Hutchinson RA, Witte KW, Newby GP.  Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm . 1988;22:252-259.
51.
Bjornson DC, Hiner WO, Potyk RP, et al.  Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm . 1993;50:1875-1884.
52.
Dukes MNG.  Economic costs of adverse drug reactions. PharmacoEconomics . 1992;1:153-154.Article
×